These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 814855)

  • 1. Preclinical safety testing of new drugs.
    Keysser CH
    Ann Clin Lab Sci; 1976; 6(2):197-205. PubMed ID: 814855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic and metabolic studies in the development of drugs].
    Vereczkey L
    Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical testing in the development of probiotics: a regulatory perspective with Bacillus strains as an example.
    Sorokulova I
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S92-5; discussion S144-51. PubMed ID: 18181731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit and risk of organic ultraviolet filters.
    Nohynek GJ; Schaefer H
    Regul Toxicol Pharmacol; 2001 Jun; 33(3):285-99. PubMed ID: 11407932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of requirements in the European Union and United States of America for pre-clinical viral safety testing of veterinary vaccines.
    Sheridan S; Coughlin J
    Biologicals; 2010 May; 38(3):340-5. PubMed ID: 20400329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing combination drugs in preclinical studies.
    Lodola A
    Methods Mol Biol; 2011; 691():3-16. PubMed ID: 20972744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ICH S5(R2) guideline for the testing of medicinal agents.
    Wise LD
    Methods Mol Biol; 2013; 947():1-11. PubMed ID: 23138891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive toxicology guidelines: comparison and application.
    Beltrame D; Mazué G
    Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of teratogenic potential of therapeutic agents: preclinical toxicology.
    Frederick GL
    Clin Invest Med; 1985; 8(4):323-7. PubMed ID: 4075617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of current preclinical testing strategies for bacterial vaccines.
    Falk LA; Chandler DK; Richman P
    Dev Biol Stand; 1998; 95():25-9. PubMed ID: 9855411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
    Parkinson C; Thomas KE; Lumley CE
    Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.